Pharma

The Factory

The manufacturing layer every blockbuster runs through

TMO — Thermo Fisher Scientific

The picks and shovels of drug development: lab instruments, bioprocessing, and contract manufacturing for the whole industry — whoever wins the drug wars, the tools bill gets paid.

market cap $230B · revenue $46B (research snapshot; the live map shows current data)

CATALENT — Catalent (Novo Holdings) (private)

The fill-finish specialist that put the pens in the GLP-1 boom — acquired by Novo Holdings for $16.5B (closed December 2024), transferring key sterile-fill sites directly to Novo Nordisk to lock up Wegovy supply.

valuation $17B (research snapshot; the live map shows current data)

The GLP-1 Duopoly

The two companies that own the weight-loss gold rush

LLY — Eli Lilly

The center of the map: Mounjaro and Zepbound made tirzepatide the best-selling drug franchise in pharma history, and Foundayo (orforglipron) — the once-daily oral GLP-1 pill approved in April 2026 — opened the floodgates to needle-averse patients without food/water restrictions.

Why it matters: Everyone else on this map is either chasing the obesity franchise, supplying it, deciding whether to pay for it, or watching their own patents expire while Lilly compounds.

Outlook: The small-molecule pill scales at traditional pharma margins rather than constrained biologics lines. With CVS Caremark restoring Zepbound to preferred formularies and unblocking Foundayo, the multi-blockbuster franchise is targeting $80B+ in 2026 revenue.

market cap $1.12T · revenue $72B (research snapshot; the live map shows current data)

NVO — Novo Nordisk

The Danish pioneer that built the modern obesity market with Ozempic and Wegovy — now navigating a two-front war: trial competition from tirzepatide (with CagriSema REIMAGINE Phase 3 data awaiting a late-2026 FDA decision) and compounder pushback that drove the March 2026 Hims distribution pact.

market cap $205B · revenue $51B (research snapshot; the live map shows current data)

The Challengers

The long shots and side doors into the same $150B prize

VKTX — Viking Therapeutics

The pure-play long shot: dual GLP-1/GIP agonist VK2735 advancing in Phase 3 subcutaneous trials (VANQUISH-1/2) with oral tablets entering Phase 3 in late 2026 — a ~$4B biotech betting its clean profile can carve out a lucrative slice from the duopoly.

market cap $4B (research snapshot; the live map shows current data)

HIMS — Hims & Hers

The direct-to-consumer weight-loss ramp: built massive subscriber scale on compounded GLP-1s during shortages, then legitimized its distribution via a March 2026 pact with Novo Nordisk to sell authentic FDA-approved Wegovy and Ozempic on its telehealth platform.

market cap $7B · revenue $3B (research snapshot; the live map shows current data)

The Patent Cliff

The old guard racing expiring patents with M&A war chests

PFE — Pfizer

The post-COVID giant confronting a steep patent cliff ($21B+ losing exclusivity through 2028), betting big on its Metsera acquisition with 10 Phase 3 trials initiated for berobenatide (MET-097i) targeting a 2028 obesity launch.

Outlook: Raised full-year 2026 revenue guidance to $60.5B–$62.5B on non-COVID portfolio strength (+18% in newly launched/acquired products), while targeting $9.7B in net cost savings through 2029 to offset patent expiries.

market cap $160B · revenue $64B (research snapshot; the live map shows current data)

MRK — Merck

Keytruda is the ~$31B cancer franchise that powers half the company. With the 2028 IV patent cliff looming, Merck launched subcutaneous Keytruda Qlex (approved late 2025; $463M in Q2 2026) to rapidly transition patients to a 1-to-2-minute injection before generic erosion hits.

market cap $366B · revenue $66B (research snapshot; the live map shows current data)

ABBV — AbbVie

The patent-cliff masterclass: absorbed Humira generic erosion as Skyrizi and Rinvoq surged double-digits past peak Humira sales, proving that a dominant immunology portfolio can out-execute a $20B cliff.

market cap $451B · revenue $64B (research snapshot; the live map shows current data)

JNJ — Johnson & Johnson

The AAA-rated healthcare fortress: Innovative Medicine blockbusters (Darzalex, Tremfya) and MedTech tracking toward $100B+ annual revenue in 2026, absorbing Stelara biosimilar entry with barely a dent in growth.

market cap $646B · revenue $96B (research snapshot; the live map shows current data)

BMY — Bristol Myers Squibb

Replacing Revlimid, Eliquis, and Opdivo with a high-conviction Growth Portfolio: scaling the Cobenfy (KarXT) schizophrenia launch and co-funding an up to $11.1B Phase 3 alliance with BioNTech on pumitamig (BNT327 PD-L1xVEGF bispecific).

market cap $136B · revenue $49B (research snapshot; the live map shows current data)

AMGN — Amgen

The biotech blue chip advancing MariTide (maridebart cafraglutide) through the massive MARITIME Phase 3 program — a monthly or less frequent GIPR antagonist / GLP-1 agonist designed to challenge weekly injections on dosing convenience.

market cap $235B · revenue $37B (research snapshot; the live map shows current data)

The mRNA Hangover

The COVID windfall is gone and Washington turned hostile

MRNA — Moderna

Rebounding from the post-pandemic trough: mFLUSIVA (mRNA-1010) won FDA approval on August 5, 2026 (reversing an earlier refusal-to-file), alongside strong Phase 3 melanoma data for its individualized cancer vaccine (intismeran autogene) co-developed with Merck.

Outlook: A deep cash pile and expanding commercial pipeline (mRESVIA, mFLUSIVA) support the multi-year turnaround, even as HHS contract realignments and vaccine policy scrutiny demand clinical precision.

market cap $55B · revenue $2B (research snapshot; the live map shows current data)

BNTX — BioNTech

Parlaying its way out of the post-COVID hangover with ~€16.6B in cash and a high-stakes oncology pivot: co-advancing pumitamig (BNT327, PD-L1xVEGF bispecific) across multiple Phase 3 lung cancer trials under an $11.1B alliance with Bristol Myers Squibb.

market cap $24B · revenue $3B (research snapshot; the live map shows current data)

The Referee

What gets approved — and what gets defunded

FDA / HHS

The regulatory gatekeeper: HHS under RFK Jr. scrutinized federal mRNA contracts and reshuffled advisory committees, while the FDA greenlights oral small-molecule GLP-1s, subQ conversions, and next-generation bispecifics.

The Toll Booth

The insurers and PBMs who decide what gets covered

UNH — UnitedHealth

The largest payer in America — UnitedHealthcare commercial/Medicare plans plus Optum PBM and physician networks. Directs over $450B in healthcare spend and dictates prior-authorization barriers for GLP-1 coverage.

market cap $353B · revenue $450B (research snapshot; the live map shows current data)

CVS — CVS Health (Caremark)

Pharmacy powerhouse plus Caremark: after making Wegovy preferred in 2025, the PBM announced it will add Zepbound back as a preferred option effective October 1, 2026, and unblocked oral Foundayo in June 2026, demonstrating its pricing leverage over both duopolists.

market cap $119B · revenue $415B (research snapshot; the live map shows current data)

The Waiting Room

Where the money ultimately comes from

The Patient

A projected $150B+ obesity market by 2030 on top of the largest total prescription drug bill on earth. With oral pills (Foundayo) and monthly shots (MariTide) overcoming needle anxiety, patient demand remains boundless — but payer coverage dictates who actually gets filled.

Relationships on the map

• Catalent (Novo Holdings) supplies Novo Nordisk — Fill-finish capacity
  Novo Holdings completed its $16.5B acquisition of Catalent, transferring key fill-finish sites directly to Novo Nordisk to lock up Wegovy pen supply.
• Thermo Fisher Scientific supplies Eli Lilly — Bioprocessing & tools
  The instruments, consumables, and bioprocessing capacity under every blockbuster pipeline on this map.
• Eli Lilly competes with Novo Nordisk — The obesity crown
  Tirzepatide and the oral Foundayo launch opened a wide lead, while Novo defends with Wegovy, oral semaglutide, and CagriSema's pending FDA review.
• Viking Therapeutics competes with Eli Lilly — The next pill & shot
  VK2735's subcutaneous Phase 3 (VANQUISH) and oral formulations challenge Zepbound and Foundayo on tolerability and weight loss.
• Novo Nordisk supplies Hims & Hers — Wegovy via telehealth
  Novo partnered with Hims & Hers in March 2026 to distribute authentic Wegovy directly through telehealth, resolving compounded semaglutide disputes.
• Amgen competes with Eli Lilly — MariTide vs Zepbound
  A monthly shot against a weekly one: MariTide is Amgen’s high-stakes bid to make extended dosing intervals the competitive wedge.
• Pfizer competes with Eli Lilly — The $10B gatecrash
  Pfizer is running 10 Phase 3 trials for Metsera's berobenatide (MET-097i), targeting a 2028 obesity launch to replace patent cliff revenues.
• Pfizer partners with Bristol Myers Squibb — Eliquis JV
  The Eliquis alliance generates massive cash flow for both, but impending patent loss forces both to fund replacement pipelines.
• AbbVie competes with Johnson & Johnson — Immunology turf
  Skyrizi and Rinvoq vs Tremfya and Darzalex across psoriasis, arthritis, and IBD — the highest-grossing non-obesity turf war in pharma.
• Pfizer partners with BioNTech — Comirnaty JV
  The COVID vaccine partnership that minted both companies — now a maturing cash flow baseline as BioNTech pivots to oncology.
• Moderna competes with BioNTech — mRNA survivors
  The two mRNA pioneers navigating post-pandemic commercial realities, diversified oncology pipelines, and shifting vaccine policy.
• Merck partners with Moderna — Cancer-vaccine bet
  Merck co-develops Moderna's individualized neoantigen therapy (intismeran autogene / mRNA-4157) with Keytruda in Phase 3 melanoma and NSCLC.
• Bristol Myers Squibb partners with BioNTech — BNT327 bispecific
  BMS committed up to $11.1B to co-develop pumitamig (BNT327), BioNTech's Phase 3 PD-L1xVEGF bispecific antibody.
• Novo Nordisk supplies CVS Health (Caremark) — Formulary preferred
  Caremark kept Wegovy as a preferred GLP-1 on commercial formularies while negotiating rebate terms with both duopolists.
• Eli Lilly supplies CVS Health (Caremark) — Formulary restoration
  CVS Caremark restored Zepbound to preferred status for October 2026 and removed the new-to-market block on Foundayo.
• UnitedHealth competes with CVS Health (Caremark) — Managed-care rivals
  Optum vs Caremark: two vertically integrated healthcare giants fighting over employer contracts, PBM rebates, and specialty pharmacy margins.
• Eli Lilly supplies The Patient — Zepbound & Foundayo (~$35B/yr)
  The tirzepatide and orforglipron franchises represent the fastest-growing drug portfolio in pharmaceutical history.
• Merck supplies The Patient — Keytruda & Qlex (~$31B/yr)
  The premier cancer blockbuster transitioning patients to subcutaneous Keytruda Qlex ahead of 2028 IV patent expiry.
• UnitedHealth supplies The Patient — The coverage gate
  Commercial plan designs, deductibles, and prior authorizations determine which patients actually get their GLP-1 prescriptions filled.